Personen, die ein erhöhtes Risiko für schwere oder chronische Verläufe einer Hepatitis B haben, wird zur Impfung gegen Hepatitis B (Hep B) geraten. Dazu gehören Menschen, die mit HIV leben (PLWH). Von ...

Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...

Dynavax Technologies Corporation (NASDAQ:DVAX), a profitable pharmaceutical company with strong financial health according to ...

EMERYVILLE, Calif. - Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company with a ...

Dynavax Technologies Corporation (the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced the following changes to its Board of ...

EMERYVILLE, Kalifornien - Dynavax Technologies Corporation (NASDAQ: DVAX ), ein biopharmazeutisches Unternehmen in der kommerziellen Phase mit einer Marktkapitalisierung von 1,67 Milliarden US-Dollar ...

An update from Dynavax ( (DVAX) ) is now available. Dynavax announced a 26% year-over-year increase in net product revenue for HEPLISAV-B in 2024, reaching approximately $268 million. The company ...

The company’s Heplisav-B vaccine, which is the only two-dose adult Hepatitis B vaccine, reported a significant year-over-year sales increase, reaching the upper end of the guidance for 2024.

Analyst Phil Nadeau of TD Cowen maintained a Buy rating on Dynavax (DVAX – Research Report), retaining the price target of $25.00. Discover outperforming stocks and invest smarter with Top Smart ...

"We are excited to announce that HEPLISAV-B has achieved record annual revenue in 2024, reflecting 26% growth year-over-year, and positioning us at the upper tier of our updated guidance range.